Physician profile
Grant William Reed
NPI 1922329051
$235,061.24
in general payments reported to CMS, 2019-2025
13 companies · $96K in 2025
The $96K reported for 2025 was more than what 99% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $111 · 2021: $16.00 · 2022: $5,414 · 2023: $24K · 2024: $108K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $171K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Travel and Lodging: $13K · Food and Beverage: $9,584 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,000 · Long Term Medical Supply Or Device Loan: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $171,159.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,763.13 |
| Travel and Lodging | $13,339.56 |
| Food and Beverage | $9,584.18 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,000.00 |
| Long Term Medical Supply Or Device Loan | $281.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $142,816.16 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $61,002.45 | 2019-2025 | Clinical Trial Product, Vitalyst, General - Structural Heart |
| Abbott Laboratories | $20,549.97 | 2019-2025 | Navitor, Portico, Mitraclip |
| Medtronic, INC. | $10,126.92 | 2021-2025 | Corevalve Evolut R, Onyx Frontier |
| Cardiovascular Systems INC. | $276.12 | 2023 | Diamondback Coronary |
| Bayer Healthcare Pharmaceuticals INC. | $136.70 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $44.62 | 2023-2025 | |
| Opsens INC. | $24.90 | 2019 | |
| Pfizer INC. | $17.91 | 2024 | |
| Becton, Dickinson and Company | $16.97 | 2024 | Rotarexs 6 F X 135 Cm |
| Biotronik INC. | $16.95 | 2023 | Orsiro Mission, Pk Papyrus |
| Livanova USA, INC. | $15.81 | 2019 | |
| Siemens Medical Solutions USA, INC. | $15.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grant Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.